SK2352001A3 - New use of taxoid derivatives - Google Patents

New use of taxoid derivatives Download PDF

Info

Publication number: SK2352001A3
Authority: SK; Slovakia
Prior art keywords: group; groups; alkyl; carbon atoms; alkoxy
Prior art date: 1998-08-20

Application number

SK235-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Marie-Christine Bissery

Patricia Vrignaud

Simon Roberts

Clive Brealey

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-20

Filing date

1999-08-18

Publication date

2001-07-10

1998-08-20 Priority claimed from EP98115650A external-priority patent/EP0982028A1/en

1999-08-18 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2001-07-10 Publication of SK2352001A3 publication Critical patent/SK2352001A3/sk

Links

102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims abstract description 14
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims abstract description 14
208000029742 colonic neoplasm Diseases 0.000 claims abstract description 9
230000002159 abnormal effect Effects 0.000 claims abstract description 6
206010009944 Colon cancer Diseases 0.000 claims abstract description 5
230000004663 cell proliferation Effects 0.000 claims abstract description 4
241000124008 Mammalia Species 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 50
125000004432 carbon atom Chemical group C* 0.000 claims description 41
-1 morpholino, 1-piperazinyl Chemical group 0.000 claims description 36
125000000217 alkyl group Chemical group 0.000 claims description 35
239000003814 drug Substances 0.000 claims description 23
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
125000003545 alkoxy group Chemical group 0.000 claims description 17
229940079593 drug Drugs 0.000 claims description 17
125000005843 halogen group Chemical group 0.000 claims description 17
125000004429 atom Chemical group 0.000 claims description 14
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 14
229910052757 nitrogen Inorganic materials 0.000 claims description 14
125000004442 acylamino group Chemical group 0.000 claims description 12
125000003118 aryl group Chemical group 0.000 claims description 12
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 11
125000004093 cyano group Chemical group *C#N 0.000 claims description 11
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 9
125000000304 alkynyl group Chemical group 0.000 claims description 9
125000003342 alkenyl group Chemical group 0.000 claims description 8
125000004663 dialkyl amino group Chemical group 0.000 claims description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
125000003282 alkyl amino group Chemical group 0.000 claims description 7
125000004414 alkyl thio group Chemical group 0.000 claims description 7
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
229910052736 halogen Inorganic materials 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
125000003884 phenylalkyl group Chemical group 0.000 claims description 6
125000001424 substituent group Chemical group 0.000 claims description 6
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
125000002252 acyl group Chemical group 0.000 claims description 5
125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 5
125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
125000005117 dialkylcarbamoyl group Chemical group 0.000 claims description 5
150000002367 halogens Chemical class 0.000 claims description 5
125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
239000011593 sulfur Chemical group 0.000 claims description 5
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims description 4
125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 4
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims description 4
125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 4
125000003710 aryl alkyl group Chemical group 0.000 claims description 4
125000004104 aryloxy group Chemical group 0.000 claims description 4
125000000623 heterocyclic group Chemical group 0.000 claims description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
125000005118 N-alkylcarbamoyl group Chemical group 0.000 claims description 3
125000003302 alkenyloxy group Chemical group 0.000 claims description 3
125000005129 aryl carbonyl group Chemical group 0.000 claims description 3
125000005110 aryl thio group Chemical group 0.000 claims description 3
125000004465 cycloalkenyloxy group Chemical group 0.000 claims description 3
125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
125000001544 thienyl group Chemical group 0.000 claims description 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
125000005133 alkynyloxy group Chemical group 0.000 claims description 2
150000001602 bicycloalkyls Chemical group 0.000 claims description 2
125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
125000002541 furyl group Chemical group 0.000 claims description 2
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
238000009169 immunotherapy Methods 0.000 claims description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
238000001959 radiotherapy Methods 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
239000012453 solvate Substances 0.000 claims description 2
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 3
239000011203 carbon fibre reinforced carbon Substances 0.000 claims 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 1
230000008512 biological response Effects 0.000 claims 1
125000001624 naphthyl group Chemical group 0.000 claims 1
238000000034 method Methods 0.000 abstract description 18
230000036457 multidrug resistance Effects 0.000 abstract description 3
210000004027 cell Anatomy 0.000 description 29
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 23
229960003668 docetaxel Drugs 0.000 description 20
206010028980 Neoplasm Diseases 0.000 description 19
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 14
YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
239000002168 alkylating agent Substances 0.000 description 8
229940100198 alkylating agent Drugs 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
230000000694 effects Effects 0.000 description 8
230000008569 process Effects 0.000 description 8
229960004679 doxorubicin Drugs 0.000 description 7
239000002585 base Substances 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
231100000331 toxic Toxicity 0.000 description 5
230000002588 toxic effect Effects 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 4
229910052783 alkali metal Inorganic materials 0.000 description 4
230000000259 anti-tumor effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 4
238000012360 testing method Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000001028 anti-proliverative effect Effects 0.000 description 3
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
238000010511 deprotection reaction Methods 0.000 description 3
230000032050 esterification Effects 0.000 description 3
238000005886 esterification reaction Methods 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
229940063683 taxotere Drugs 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
206010034133 Pathogen resistance Diseases 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical class [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
150000001351 alkyl iodides Chemical class 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
229940127093 camptothecin Drugs 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229910000105 potassium hydride Inorganic materials 0.000 description 2
NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
229910001923 silver oxide Inorganic materials 0.000 description 2
239000000758 substrate Substances 0.000 description 2
150000003462 sulfoxides Chemical class 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
150000003952 β-lactams Chemical class 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
GJFNRSDCSTVPCJ-UHFFFAOYSA-N 1,8-bis(dimethylamino)naphthalene Chemical compound C1=CC(N(C)C)=C2C(N(C)C)=CC=CC2=C1 GJFNRSDCSTVPCJ-UHFFFAOYSA-N 0.000 description 1
BQVVEYBPZZOMBA-UHFFFAOYSA-N 1-chloro-2-(1-chloro-1,2-dimethoxy-1-nitropropan-2-yl)oxy-1,2-dimethoxy-1-nitropropane Chemical group COC(Cl)([N+]([O-])=O)C(C)(OC)OC(C)(OC)C(Cl)(OC)[N+]([O-])=O BQVVEYBPZZOMBA-UHFFFAOYSA-N 0.000 description 1
PPJVXZVTPWQOQS-UHFFFAOYSA-N 1-ethoxy-1-(1-ethoxyethoxy)ethane Chemical compound CCOC(C)OC(C)OCC PPJVXZVTPWQOQS-UHFFFAOYSA-N 0.000 description 1
UUAKOKFSMXRGJP-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethoxymethoxymethyl]benzene Chemical compound C1=CC(OC)=CC=C1COCOCOCC1=CC=C(OC)C=C1 UUAKOKFSMXRGJP-UHFFFAOYSA-N 0.000 description 1
CRAJLXHBNCCDPK-UHFFFAOYSA-N 2,2,2-trichloroethyl hydrogen carbonate Chemical class OC(=O)OCC(Cl)(Cl)Cl CRAJLXHBNCCDPK-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
235000007119 Ananas comosus Nutrition 0.000 description 1
244000099147 Ananas comosus Species 0.000 description 1
229930190007 Baccatin Natural products 0.000 description 1
125000000041 C6-C10 aryl group Chemical group 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
101100497210 Solanum lycopersicum CPT5 gene Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
125000004171 alkoxy aryl group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
150000008051 alkyl sulfates Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000003849 aromatic solvent Substances 0.000 description 1
125000005239 aroylamino group Chemical group 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
201000010897 colon adenocarcinoma Diseases 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229940125890 compound Ia Drugs 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical group C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000008103 glucose Substances 0.000 description 1
231100000001 growth retardation Toxicity 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
125000003106 haloaryl group Chemical group 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
230000005917 in vivo anti-tumor Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
YLNQVTBPQUWDCZ-UHFFFAOYSA-N methyl hydrogen sulfate;hydrate Chemical class O.COS(O)(=O)=O YLNQVTBPQUWDCZ-UHFFFAOYSA-N 0.000 description 1
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
TYZYRCHEVXXLSJ-UHFFFAOYSA-N phenylmethoxymethoxymethoxymethylbenzene Chemical compound C=1C=CC=CC=1COCOCOCC1=CC=CC=C1 TYZYRCHEVXXLSJ-UHFFFAOYSA-N 0.000 description 1
239000003880 polar aprotic solvent Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
150000003459 sulfonic acid esters Chemical class 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epoxy Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK235-2001A 1998-08-20 1999-08-18 New use of taxoid derivatives SK2352001A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP98115650A EP0982028A1 (en)	1998-08-20	1998-08-20	New use of taxoid derivatives
US12384399P	1999-03-11	1999-03-11
PCT/EP1999/006292 WO2000010547A2 (en)	1998-08-20	1999-08-18	New use of taxoid derivatives

Publications (1)

Publication Number	Publication Date
SK2352001A3 true SK2352001A3 (en)	2001-07-10

Family

ID=26149552

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK235-2001A SK2352001A3 (en)	1998-08-20	1999-08-18	New use of taxoid derivatives

Country Status (15)

Country	Link
EP (1)	EP1105119A2 (et)
JP (1)	JP2002523364A (et)
KR (1)	KR20010079665A (et)
CN (1)	CN1313764A (et)
AU (1)	AU5742099A (et)
BG (1)	BG105273A (et)
CA (1)	CA2341191A1 (et)
EE (1)	EE200100082A (et)
HU (1)	HUP0104000A3 (et)
IL (1)	IL141231A0 (et)
MX (1)	MXPA01001721A (et)
NO (1)	NO20010655D0 (et)
SK (1)	SK2352001A3 (et)
TR (1)	TR200100575T2 (et)
WO (1)	WO2000010547A2 (et)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2922107B1 (fr) *	2007-10-10	2010-02-26	Aventis Pharma Sa	Nouvelles compositions a base de taxoides
CN102770131A (zh)	2009-10-29	2012-11-07	安万特医药股份有限公司	卡巴他赛的新颖抗肿瘤用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2697522B1 (fr) *	1992-10-30	1994-11-25	Rhone Poulenc Rorer Sa	Procédé de préparation de dérivés du taxane.
MA23823A1 (fr) *	1995-03-27	1996-10-01	Aventis Pharma Sa	Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2732968B1 (fr) *	1995-04-14	1997-05-16	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

1999
- 1999-08-18 WO PCT/EP1999/006292 patent/WO2000010547A2/en not_active Ceased
- 1999-08-18 CN CN99809900A patent/CN1313764A/zh active Pending
- 1999-08-18 CA CA002341191A patent/CA2341191A1/en not_active Abandoned
- 1999-08-18 SK SK235-2001A patent/SK2352001A3/sk unknown
- 1999-08-18 MX MXPA01001721A patent/MXPA01001721A/es unknown
- 1999-08-18 KR KR1020017002136A patent/KR20010079665A/ko not_active Withdrawn
- 1999-08-18 IL IL14123199A patent/IL141231A0/xx unknown
- 1999-08-18 TR TR2001/00575T patent/TR200100575T2/xx unknown
- 1999-08-18 AU AU57420/99A patent/AU5742099A/en not_active Abandoned
- 1999-08-18 JP JP2000565869A patent/JP2002523364A/ja active Pending
- 1999-08-18 HU HU0104000A patent/HUP0104000A3/hu unknown
- 1999-08-18 EE EEP200100082A patent/EE200100082A/et unknown
- 1999-08-18 EP EP99944532A patent/EP1105119A2/en not_active Withdrawn
2001
- 2001-02-07 NO NO20010655A patent/NO20010655D0/no unknown
- 2001-02-20 BG BG105273A patent/BG105273A/xx unknown

Also Published As

Publication number	Publication date
MXPA01001721A (es)	2005-06-03
HUP0104000A3 (en)	2003-01-28
EP1105119A2 (en)	2001-06-13
HUP0104000A2 (hu)	2002-04-29
BG105273A (en)	2001-11-30
WO2000010547A2 (en)	2000-03-02
IL141231A0 (en)	2002-03-10
CA2341191A1 (en)	2000-03-02
TR200100575T2 (tr)	2001-07-23
WO2000010547A3 (en)	2000-06-29
CN1313764A (zh)	2001-09-19
EE200100082A (et)	2002-06-17
AU5742099A (en)	2000-03-14
JP2002523364A (ja)	2002-07-30
NO20010655L (no)	2001-02-07
NO20010655D0 (no)	2001-02-07
KR20010079665A (ko)	2001-08-22

Publication	Publication Date	Title
BG99713A (bg)	1996-02-28	Нови таксоиди,тяхното получаване и фармацевтичнисъстави,които ги съдържат
KR100710533B1 (ko)	2007-04-23	탁소이드 유도체의 신규 용도
US5547981A (en)	1996-08-20	Taxol-7-carbazates
BG63693B1 (bg)	2002-09-30	Таксоиди, тяхното получаване и фармацевтични състави, които ги съдържат
SK2352001A3 (en)	2001-07-10	New use of taxoid derivatives
JP4986354B2 (ja)	2012-07-25	抗腫瘍活性及び抗脈管形成活性を有する半合成タキサン類
Naylor et al.	1990	Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins
SK139994A3 (en)	1995-07-11	Taxane derivatives, their preparation and compositions containing same
EP0982028A1 (en)	2000-03-01	New use of taxoid derivatives
CZ2001603A3 (cs)	2001-06-13	Způsob výroby léčivých obrazů GA/MO, při kterém léčivý obraz vzniká přímo na fólii (1,2) na bázi otisku, a to tak, že se spodní fólie (1) položí na podkladovou plochu (4) přičemž na vrchní stranu fólie (1) se nanesou barvy (3), na ně se položí vrchní fólie (2) a na takto připravené fólie (1,2) se působí tlakem, přičemž ve spodní fólii (1) i vrchní fólii (2) se vyberou nejaktivnější partie (9), které se označí, vystřihnou a následné zapaspartují.
EP0982027A1 (en)	2000-03-01	Taxoid derivatives for treating abnormal cell proliferation of the brain
MXPA01001683A (en)	2001-11-21	New use of taxoid derivatives
Kingston	2010	Plant-derived natural products as anticancer agents